

## List of annexes\*

- Annex 1** Terms of reference for the "3 by 5" Evaluation 2004–2006
- Annex 2** List of key persons interviewed
- Annex 3** List of key documents consulted
- Annex 4** Evaluation methodology
- Annex 5** Regional office and country visit notes
- Annex 5.1** *WHO Regional Office for Africa*
  - Annex 5.2** *WHO Regional Office for the Americas/PAHO*
  - Annex 5.3** *WHO Regional Office for the Eastern Mediterranean*
  - Annex 5.4** *WHO Regional Office for South-East Asia*
  - Annex 5.5** *Burkina Faso*
  - Annex 5.6** *Guyana*
  - Annex 5.7** *India*
  - Annex 5.8** *Kenya*
  - Annex 5.9** *Malawi*
  - Annex 5.10** *Mozambique*
  - Annex 5.11** *Ukraine*
- Annex 6** Presentation of the summary findings of questionnaires
- Annex 6.1** *WHO "3 by 5" country officers (COs)*
  - Annex 6.2** *National AIDS programme managers*
  - Annex 6.3** *United Nations Theme Groups on HIV/AIDS*
- Annex 7** Historical and budgetary data
- Annex 7.1** *Historical data*
  - Annex 7.2** *Mapping of 2004–2005 contributions to HIV area of work*
  - Annex 7.3** *HIV/AIDS Area of Work 2004–2005, financial update, by end of September 2005*
  - Annex 7.4** *HIV Area of Work implementation rate by end of November 2005*
  - Annex 7.5** *Department of HIV – Estimated breakdown of expenditure according to Organization-wide and office-specific expected results, 2004–2005*
  - Annex 7.6** *Name, country, date of employment and source of funding for HIV/AIDS country officers (COs) funded through "3 by 5" funds*
- Annex 8** IMAI focus study within the WHO "3 by 5" Evaluation

\*Annexes are available in electronic format on the WHO website and in a CD-Rom.

**Annex 9** Special focus studies**Annex 9.1** *The WHO/United Nations Prequalification Project***Annex 9.2** *HIV drug resistance prevention, surveillance, and monitoring***Annex 9.3** *A synopsis of antiretroviral drug pricing trends***Annex 10** The existence of ART guidelines in resource-limited countries**Annex 11** The AIDS Medicines and Diagnostics Service (AMDS) contributions to antiretroviral price reductions and access to effective and reliable supplies**Annex 12** Press clippings**Annex 12.1** *AFYA KWA WOTE, the Newsletter of the World Health Organization, Kenya, Vol. 4, No. 2, July–December 2003***Annex 12.2** *Apology over missed AIDS target – BBC News, 28 November 2005***Annex 12.3** *World Health Organization, 1 December 2005 – World AIDS Day – Message from the Director-General*

## List of appendices\*

---

**Appendix A** Steering Committee members**Appendix B** WHO/UNAIDS, 2003. *Treating 3 million by 2005. Making it happen.* The WHO Strategy.**Appendix C** WHO/UNAIDS, 2005. *Progress on the global access to HIV antiretroviral therapy. An update on "3 by 5",* June 2005.**Appendix D** WHO/UNAIDS, 2006. *Progress on global access to HIV antiretroviral therapy: A report on "3 by 5" and beyond,* March 2006.**Appendix E** WHO, 2003. *A public health approach to antiretroviral treatment: overcoming constraints.***Appendix F** WHO, 2003. *Global health sector strategy for HIV/AIDS 2003–2007.***Appendix G** WHO, 22 May 2004. Resolution WHA57.14 of the World Health Assembly: *Scaling up treatment and care within a coordinated and comprehensive response to HIV/AIDS.*

\*Appendices are available in electronic format on the WHO website and in a CD-Rom.